New redifferentiation strategies are now available to restore uptake in RAI-R cancers, while new theragnostics approaches showed promising preliminary results for advanced and aggressive forms of follicular-cell derived thyroid cancers (SSAs-targeted PRRT, PSMA-internal radiotherapy). This evidence concerns the gene FOLH1 and cancer.